US biotech Regenxbio (Nasdaq: RGNX) has successfully completed the BLA submission for its mucopolysaccharidosis II (MPS II) ...

Chinese pharmaceutical company Fosun Pharmaceutical Group (SHA: 600196) has agreed to sell its stake in private hospital ...

Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved.

The UK government plans to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject ...

Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody ...

The US Food and Drug Administration (FDA) has announced its recommendations to vaccine manufacturers for the virus strains to ...

The UK has announced plans to abolish NHS England and integrate its functions into the central government, marking a ...

USA-based Azurity Pharmaceuticals says it has completed its acquisition of Covis Group from existing investors and the ...

Sutro Biopharma (Nasdaq: STRO), a US biotechnology company, has announced significant organizational changes, including a ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

At its March meeting, the European Medicines Agency’s management board adopted the EMA’s annual report for 2024. This ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...